Drugs / Tobevibart
Tobevibart
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06070051 | Sep 2023 → Mar 2026 overdue | chronic hepatitis B virus infection | Virion Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05484206 | Sep 2022 → Sep 2026 expected | cirrhosis of liver | Vir Biotechnology, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT04423393 | May 2020 → Oct 2022 | chronic hepatitis B virus infection | Vir Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05612581 | May 2023 → Oct 2024 | chronic hepatitis B virus infection | Vir Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07142811 | Aug 2025 → Nov 2026 expected | viral hepatitis | Vir Biotechnology, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06216470 | Mar 2024 → Dec 2029 expected | chronic hepatitis B virus infection | University Health Network, Toronto | Recruiting | No outcome recorded |
| Phase 2 | NCT05461170 | Sep 2022 → Nov 2031 expected | hepatitis D virus infection | Vir Biotechnology, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04856085 | Jul 2021 → Mar 2026 | chronic hepatitis B virus infection | Vir Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07128550 | Jul 2025 → Dec 2026 expected | viral hepatitis | Vir Biotechnology, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06903338 | Mar 2025 → Dec 2026 expected | viral hepatitis | Vir Biotechnology, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tobevibart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07142811 ↗ |
| Known as | HBC34-v35-LS-XX2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314621 ↗ |
| Known as | LS-GAALIE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314621 ↗ |
| Known as | VIR-3434 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06216470 ↗ |
| Action | Inhibit | “Tobevibart, a human monoclonal antibody against hepatitis B surface antigen (HBsAg), neutralizes HBV and HDV.” PMID 40882923 ↗ Aug 2025 |
| Modality | Monoclonal antibody | “Tobevibart (VIR-3434) is an investigational, Fc-engineered human mAb that targets HBsAg with pan-genotypic neutralizing activity.” PMID 41586499 ↗ Jan 2026 |
| Route | Subcutaneous | “VIR-3434 given by subcutaneous injection” NCT04423393 ↗ |